Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Health Sciences Authority
New Drug Indication Approvals

New drug indication approval - November 2024

Audiences

Healthcare professional

Industry member

Product type

Therapeutic Products

15 January 2025

This article has been migrated from an earlier version of the site and may display formatting inconsistencies.

For the most updated information related to registered therapeutic products, please refer to the Register of Therapeutic Products.

Product information

Product Name

IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML

Active Ingredient (Strength)

Tremelimumab(20 mg/mL)

Product Registrant

ASTRAZENECA SINGAPORE PTE LTD

Date of Approval

15/11/2024

Indications:
Non-Small Cell Lung Cancer (NSCLC)
IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

Product information

Product Name

BRUKINSA™ CAPSULE 80MG

Active Ingredient (Strength)

Zanubrutinib(80mg)

Product Registrant

BEIGENE SINGAPORE PTE. LTD.

Date of Approval

26/11/2024

Indications:
BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.

Back to top